Research Paper Volume 15, Issue 23 pp 13753—13775
PBRM1 mutation and WDR72 expression as potential combinatorial biomarker for predicting the response to Nivolumab in patients with ccRCC: a tumor marker prognostic study
Figure 1. Expression and prognostic significance of WDR72 in ccRCC. (A) Overlapping genes that can improve prognosis including OS, DSS and PFI (top 20 genes) in ccRCC from TCGA data set (Left panel). Overall survival analysis for the prognostic significance of 6 overlapping genes in ccRCC (Right panel). (B) Analysis of the prognostic significance of WDR72 expression in ccRCC patients (OS, left panel; DSS, middle panel; PFI, right panel). (C) WDR72 expression in normal renal tissues and ccRCC tissues. (D) WDR72 expression in ccRCC tissues and paired adjacent normal renal tissues. (E) WDR72 expression in early (I and II) versus late (III and IV) pathological stages in ccRCC. (F) WDR72 protein expression detected by immunohistochemistry staining in RCC tissues (top panel) and normal renal tissues (bottom panel) based on The Human Protein Atlas database (Left panel). Intensity of WDR72 protein was divided into four levels, including Negative, Weak, Moderate and Strong. Abbreviations: WDR72, WD repeat-containing protein 72; ccRCC, clear cell renal cell carcinoma; HR, hazard ratio; CI, confidence interval; OS, overall survival; DSS, disease specific survival; PFI, progress free interval; TCGA, The Cancer Genome Atlas. ***P <0.001.